TNBC is estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) negative breast cancer, is not sensitive to common endocrine therapy and targeted therapy, has a poor prognosis, and is prone to early recurrence and metastasis [3]. This evidence concerns the gene ERBB2 and breast carcinoma.